Abstract
We investigated the clinical effects of pazufloxacin (PZFX), a newly developed oral quinolone agent, in the gynecological infectious diseases.
PZFX was orally administered to 11 patients with Bartholin's abscess, pyosalpinx, salpingitis and cervicitis.
Among these cases, 8 were evaluated as effective, 3 as unknown.(The efficacy rate was 100%.)
Of the 3 cases, 1 case with cervicitis was excluded because of infection with Trichomonas. The 2 cases of salpingitis were excluded because of under unclar symptoms of infection.
PZFX was effective for gynecological infectious disease.
Bacteriologically 6 species, 10 strains were isolated from 7 patients.(The eradication rate was 90%.)
No side effects were observed during the treatment.
